Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA, Kohei; Ozguroglu, Mustafa; BANG, Yung-Jue; DI BARTOLOMEO, Maria; MANDALA, Mario; RYU, Min-Hee; FORNARO, Lorenzo; OLESINSKI, Tomasz; CAGLEVIC, Christian; CHUNG, Hyun; MURO, Kei; Goekkurt, Eray; MANSOOR, Wasat; MCDERMOTT, Raymond; SHACHAM-SHMUELI, Einat; CHEN, Xinqun; MAYO, Carlos; KANG, S.; OHTSU, Atsushi; Fuchs, Charles

doi:10.1016/s0140-6736(18)31257-1

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA K., Ozguroglu M., BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., ...More

LANCET, vol.392, no.10142, pp.123-133, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 392 Issue: 10142
Publication Date: 2018
Doi Number: 10.1016/s0140-6736(18)31257-1
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.123-133
Istanbul University Affiliated: Yes

Abstract

Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.